Return to growth: Pfizer thanks Hospira and looks to biosimilars
Pfizer has attributed Hospira’s sterile injectables and biosimilar assets to its return to growth, offsetting 17 quarters of declining sales.
Archives for May 3, 2016
Biogen haemophilia spin-out to develop gene therapies and long-acting factors
The new entity will focus on a haemophilia pipeline utilising the XTEN half-life extension technology, bispecific antibodies and gene therapies.